MA28748B1 - Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques - Google Patents

Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques

Info

Publication number
MA28748B1
MA28748B1 MA29627A MA29627A MA28748B1 MA 28748 B1 MA28748 B1 MA 28748B1 MA 29627 A MA29627 A MA 29627A MA 29627 A MA29627 A MA 29627A MA 28748 B1 MA28748 B1 MA 28748B1
Authority
MA
Morocco
Prior art keywords
self
lipid excipients
galenic
applications
emulsifiable
Prior art date
Application number
MA29627A
Other languages
English (en)
Inventor
Jean Pachot
Chicq Serge Segot
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MA28748B1 publication Critical patent/MA28748B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention a pour objet de nouvelles formulations galéniques permettant d'améliorer l'absorption intestinale de principes actifs administrés par voie orale, leur procédé de préparation ainsi que l'application d'excipients lipidiques associés à un ou des tensioactifs et un ou des co-tensioactifs pour inhiber les pompes à efflux.
MA29627A 2004-07-27 2007-01-23 Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques MA28748B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0408269A FR2873585B1 (fr) 2004-07-27 2004-07-27 Nouvelles formulations galeniques de principes actifs

Publications (1)

Publication Number Publication Date
MA28748B1 true MA28748B1 (fr) 2007-07-02

Family

ID=34951660

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29627A MA28748B1 (fr) 2004-07-27 2007-01-23 Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques

Country Status (18)

Country Link
US (2) US20080193519A1 (fr)
EP (1) EP1771154A1 (fr)
JP (1) JP2008508191A (fr)
KR (1) KR20070046819A (fr)
CN (1) CN101001608A (fr)
AU (1) AU2005273839A1 (fr)
BR (1) BRPI0513622A (fr)
CA (1) CA2579449A1 (fr)
FR (1) FR2873585B1 (fr)
IL (1) IL180714A0 (fr)
MA (1) MA28748B1 (fr)
MX (1) MX2007001141A (fr)
NO (1) NO20070354L (fr)
NZ (1) NZ552715A (fr)
RU (1) RU2381789C2 (fr)
TW (1) TW200616640A (fr)
WO (1) WO2006018501A1 (fr)
ZA (1) ZA200700553B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1867323A1 (fr) * 2006-06-13 2007-12-19 Farmatron Ltd. Formulations pharmaceutiques avec pénétration améliorée à travers des barrières biologiques
MX2010001730A (es) * 2007-08-21 2010-03-10 Basilea Pharmaceutica Ag Composicion antimicotica.
EP2488022B1 (fr) 2009-10-16 2018-01-10 Mochida Pharmaceutical Co., Ltd. Compositions
JP2013209294A (ja) * 2010-07-30 2013-10-10 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 液状医薬組成物
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
KR101542364B1 (ko) * 2014-10-31 2015-08-07 대화제약 주식회사 탁산을 포함하는 경구 투여용 약학 조성물
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
AU2019396217A1 (en) * 2018-12-10 2021-07-08 Halo Science LLC Stable formulations of anesthetics and associated dosage forms
CZ309587B6 (cs) * 2021-01-22 2023-05-03 Oncora S.R.O. Mikroemulzní prekoncentrát s obsahem kladribinu a způsob jeho přípravy
CN114246827B (zh) * 2022-01-04 2023-04-11 中山大学 一种鱼油微乳制剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8916901D0 (en) * 1989-07-24 1989-09-06 Sandoz Ltd Improvements in or relating to organic compounds
FR2710535B1 (fr) * 1993-09-30 1995-11-24 Gattefosse Ets Sa Composition à usage pharmaceutique ou cosmétique apte à former une microémulsion.
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
EP0933367A1 (fr) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Dérivés d'acylguanidine comme inhibiteurs de résorbtion osseuse et comme antagonistes de récepteur vitronectine
IL137423A0 (en) * 1998-01-23 2001-07-24 Aventis Pharma Gmbh Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
CN100341485C (zh) * 1998-04-01 2007-10-10 斯凯伊药品加拿大公司 抗癌组合物
AU4989299A (en) * 1998-07-14 2000-02-07 Em Industries, Inc. Microdisperse drug delivery systems
GB0003685D0 (en) * 2000-02-17 2000-04-05 Univ Cardiff Sensitisation of cellular material
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
JP4464814B2 (ja) * 2002-05-14 2010-05-19 アバーント・ファーマシューティカルズ・（インディア）・リミテッド アントラニル酸誘導体の水和物の製造方法

Also Published As

Publication number Publication date
IL180714A0 (en) 2007-06-03
NO20070354L (no) 2007-04-17
JP2008508191A (ja) 2008-03-21
EP1771154A1 (fr) 2007-04-11
CA2579449A1 (fr) 2006-02-23
NZ552715A (en) 2010-12-24
RU2007107199A (ru) 2008-09-10
ZA200700553B (en) 2008-05-28
US20080193519A1 (en) 2008-08-14
CN101001608A (zh) 2007-07-18
TW200616640A (en) 2006-06-01
WO2006018501A1 (fr) 2006-02-23
US20110104268A1 (en) 2011-05-05
KR20070046819A (ko) 2007-05-03
FR2873585A1 (fr) 2006-02-03
RU2381789C2 (ru) 2010-02-20
AU2005273839A1 (en) 2006-02-23
FR2873585B1 (fr) 2006-11-17
MX2007001141A (es) 2007-04-19
BRPI0513622A (pt) 2008-05-13
WO2006018501A8 (fr) 2007-03-01

Similar Documents

Publication Publication Date Title
MA28748B1 (fr) Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques
WO2003105800A3 (fr) Forme galenique, se presentant sous forme de film adherant a la muqueuse, pour l'administration de principes actifs du cannabis
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
MA31496B1 (fr) Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
EA200301018A1 (ru) Доставляемая перорально фармацевтическая композиция, включающая активное соединение, содержащее аминосульфонильную группу (ингибитор cox-2), полиэтиленгликоль и улавливающий свободные радикалы антиоксидант
TNSN06439A1 (fr) Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique
MA31849B1 (fr) Nouveaux dérivés de pyrimidine
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
MA30807B1 (fr) Compositions pharmaceutiques.
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
BRPI0516132A (pt) compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica
AU2007247480A8 (en) Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and an NSAID
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
WO2008017867A3 (fr) Composition orale solide antirétrovirale
EA200870545A1 (ru) Новые гетероциклические соединения
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
DE60219005D1 (de) Feste pharmazeutische formulierung enthaltend modafinil
MA30779B1 (fr) Comprimes pediatriques de capecitabine
NO20070580L (no) Behandling av cancer.
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
DK1267831T3 (da) Hidtil ukendt selvemulgerende system til lægemiddelindgift
MA32964B1 (fr) Formulation a effet retard d'octreotide avec niveau d'exposition constamment eleves
EA200800360A1 (ru) Формуляции с высоким содержанием лекарства и дозированные формы